Skip to main content

IDH1 Mutation clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

    open to eligible people ages 18 years and up

    This phase I/II trial studies the side effects and how well BGB-290 and temozolomide work in treating patients with gliomas (brain tumors) with IDH1/2 mutations that have come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating patients with recurrent gliomas.

    at UCLA

Last updated: